THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS

被引：0
|
作者：
Hou, J. [1 ]
Du, X. [2 ]
Jin, J. [3 ]
Cai, Z. [3 ]
Chen, F. [4 ]
Zhou, D. [5 ]
Yu, L. [6 ]
Ke, X. [7 ]
Li, X. [8 ]
Wu, D. [9 ]
Meng, F. [10 ]
Ai, H. [11 ]
Zhang, J. [12 ]
Chen, N. [12 ]
Mei, J. [12 ]
Wang, J. [13 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[5] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[6] 301 Mil Hosp, Beijing, Peoples R China
[7] Peking Univ, Hosp 3, Beijing, Peoples R China
[8] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[9] Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[11] 307 PLA Hosp, Beijing, Peoples R China
[12] Celgene Corporat, Summit, NJ USA
[13] Changhai Hosp, Shanghai, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P813
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [31] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [32] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [33] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)
    Bensinger, W.
    Wang, M.
    Orlowski, R. Z.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrall, N. Y.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] PX-171-006, A PHASE IB DOSE-ESCALATION STUDY OF CARFILZOMIB plus LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Wang, M.
    Bensinger, W.
    Orlowski, R.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrail, N.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 157
  • [35] A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    White, Darrell J.
    Bahlis, Nizar J.
    Venner, Christopher P.
    Schiller, Gary J.
    Gasparetto, Cristina J.
    Sutherland, Heather J.
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Bensinger, William
    Lipe, Brea C.
    Chen, Christine I.
    Del Col, Aldo
    Kauffman, Michael G.
    Shacham, Sharon
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    LeBlanc, Richard
    BLOOD, 2017, 130
  • [36] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell J.
    Reece, Donna
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Deng, Wei
    Kroog, Glenn
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [37] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
    Matous, Jeffrey
    Siegel, David S.
    Lonial, Sagar
    Harvey, R. Donald
    Kasserra, Claudia
    Li, Yan
    Chen, Min
    Doerr, Thomas
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian
    Shah, Jatin J.
    BLOOD, 2014, 124 (21)
  • [38] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [39] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
    Dimopoulos, Meletios
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ardizzoia, Antonio
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Li, Yan
    Bacon, Pamela
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
  • [40] A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
    Reu, Frederic J.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Lazarus, Hillard M.
    Dean, Robert M.
    Faiman, Beth
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt E.
    Valent, Jason Neil
    Samaras, Christy Joy
    Sobecks, Ronald M.
    McCowen, Linda
    Elberson, Jamie
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Smith, Mitchell R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345